drugset / Trial / NCT00847626

Efficacy and Safety of Azilsartan Medoxomil Combined With Chlorthalidone in Participants With Moderate to Severe Hypertension

NCT00847626

Phase 3 Completed 1711 enrolled Takeda
RandomizedFactorialQuadruple-blindTreatment

Summary

The purpose of this study is to determine the efficacy and safety of azilsartan medoxomil combined with chlorthalidone, once daily (QD), in participants with moderate to severe hypertension.

Timeline

Start
2009-01
Primary completion
2010-05
Completion
2010-07

Drugs

EvaluationDrugModalityDoseRoute
Subject Azilsartan medoxomil Other / unclassified 20 mg Oral
Subject Azilsartan medoxomil Other / unclassified 40 mg Oral
Subject Azilsartan medoxomil Other / unclassified 80 mg Oral
Subject Chlorthalidone Other / unclassified 12.5 mg Oral
Subject Chlorthalidone Other / unclassified 25 mg Oral

Indications